文献速递肝病消化道肿瘤与早癌

TSC1/2突变定义一种侵袭性行为且具治疗意义的肝细胞癌分子亚群

TSC1/2 mutations define a molecular subset of HCC with aggressive behaviour and treatment implication.
PubMed 文献 · Gut · 2016-12-14

研究对慢性HBV相关肝细胞癌(HCC)样本及细胞系进行二代测序,筛查mTOR通路相关基因突变。发现TSC1/2基因在HCC中频繁突变(16.2%,n=18/111),突变导致mTOR下游活性抑制功能受损并促进侵袭性行为,TSC突变细胞对雷帕霉素敏感性增高。

要点

  • HBV相关HCC中TSC1/2基因突变频率为16.2%(n=18/111)。
  • TSC1/2突变通过不同机制破坏其抑制mTOR下游活性的功能,导致更具侵袭性的肿瘤行为。
  • TSC突变细胞经雷帕霉素处理后集落形成能力降低,TSC2突变PDTX模型显示对雷帕霉素超敏的治疗获益。

核心结论

  • 研究提示HBV相关HCC中存在先前未记录的突变依赖性mTOR过度激活及频繁的TSC1/2突变
  • 这些突变定义了具有mTOR信号通路遗传异常的HCC分子亚群,可能对有效的特异性药物治疗具有潜在意义

研究设计与样本

  • 研究对人工HCC样本和细胞系进行二代测序,系统筛查mTOR通路相关基因突变并按复发频率评估突变基因
  • 用免疫组化评估人HCC样本中TSC1、TSC2和pRPS6蛋白表达
  • 用集落形成实验评估HCC细胞系对雷帕霉素的敏感性,并用患者来源肿瘤异种移植(PDTX)模型进一步测试治疗

主要发现

  • 在HBV相关HCC样本中鉴定并确认多个mTOR组件为复发性突变
  • 检测到HCC样本中TSC1和TSC2基因频繁突变,频率为16.2%(n=18/111)
  • TSC1/2突变谱可能通过不同机制破坏内源性基因抑制下游mTOR活性的功能,并导致更具侵袭性的肿瘤行为
  • 在HCC细胞系和PDTX模型中也观察到TSC1和TSC2的突变性破坏
  • TSC突变细胞经雷帕霉素处理后集落形成能力降低;使用生物学相关的TSC2突变PDTX模型证明了对雷帕霉素超敏的治疗获益

关键数值与推荐

  • HCC样本中TSC1和TSC2基因突变频率为16.2%(n=18/111)

临床怎么用

  • 作者认为这些发现定义了具有mTOR信号通路遗传异常的HCC分子亚群,可能对有效的特异性药物治疗具有潜在意义

局限性

  • 原文未报告局限性

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: We investigated the mutational landscape of mammalian target of rapamycin (mTOR) signalling cascade in hepatocellular carcinomas (HCCs) with chronic HBV background, aiming to evaluate and delineate mutation-dependent mechanism of mTOR hyperactivation in hepatocarcinogenesis. DESIGN: We performed next-generation sequencing on human HCC samples and cell line panel. Systematic mutational screening of mTOR pathway-related genes was undertaken and mutant genes were evaluated based on their recurrence. Protein expressions of tuberous sclerosis complex (TSC)1, TSC2 and pRPS6 were assessed by immunohistochemistry in human HCC samples. Rapamycin sensitivity was estimated by colony-formation assay in HCC cell lines and the treatment was further tested using our patient-derived tumour xenograft (PDTX) models. RESULTS: We identified and confirmed multiple mTOR components as recurrently mutated in HBV-associated HCCs. Of significance, we detected frequent (16.2%, n=18/111) mutations of TSC1 and TSC2 genes in the HCC samples. The spectrum of TSC1/2 mutations likely disrupts the endogenous gene functions in suppressing the downstream mTOR activity through different mechanisms and leads to more aggressive tumour behaviour. Mutational disruption of TSC1 and TSC2 was also observed in HCC cell lines and our PDTX models. TSC-mutant cells exhibited reduced colony-forming ability on rapamycin treatment. With the use of biologically relevant TSC2-mutant PDTXs, we demonstrated the therapeutic benefits of the hypersensitivity towards rapamycin treatment. CONCLUSIONS: Taken together, our findings suggest the significance of previously undocumented mutation-dependent mTOR hyperactivation and frequent TSC1/2 mutations in HBV-associated HCCs. They define a molecular subset of HCC having genetic aberrations in mTOR signalling, with potential significance of effective specific drug therapy.

来源:Gut,查看原文。版权归原作者所有。

引用

  1. Ho DWH, Chan LK, Chiu YT, et al. TSC1/2 mutations define a molecular subset of HCC with aggressive behaviour and treatment implication. Gut. 2016. PMID: 27974549. doi:10.1136/gutjnl-2016-312734

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。